Nelipepimut-S

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Nelipepimut-S
DrugBank Accession Number
DB06226
Background

Not Available

Type
Biotech
Groups
Investigational
Biologic Classification
Vaccines
Other vaccines
Synonyms
  • Nelipepimut S
  • Nelipepimut-S
External IDs
  • E-75 PEPTIDE
  • E75
  • E75 PEPTIDE

Pharmacology

Indication

Investigated for use/treatment in prostate cancer and breast cancer.

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action

NeuVax is a HER2/neu peptide-based T-cell immunotherapy aimed at preventing disease recurrence and prolonging survival in cancer patients that have tumors which express the HER2/neu oncoprotein. To date, clinical study results have demonstrated that NeuVax significantly reduces the rate of cancer recurrence while showing minimal side effects. [Apthera Press release]

TargetActionsOrganism
UHLA class I histocompatibility antigen, A-2 alpha chainNot AvailableHumans
UHLA class I histocompatibility antigen, A-3 alpha chainNot AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
International/Other Brands
NeuVax (Apthera, Inc.)

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
7M0A29CD8B
CAS number
160212-35-1

References

General References
  1. Peoples GE, Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S, Dehqanzada ZA, Gurney JM, Woll MM, Ryan GB, Storrer CE, Craig D, Ioannides CG, Ponniah S: Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res. 2008 Feb 1;14(3):797-803. doi: 10.1158/1078-0432.CCR-07-1448. [Article]
  2. Hueman MT, Stojadinovic A, Storrer CE, Dehqanzada ZA, Gurney JM, Shriver CD, Ponniah S, Peoples GE: Analysis of naive and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine. Cancer Immunol Immunother. 2007 Feb;56(2):135-46. Epub 2006 Jun 17. [Article]
Wikipedia
E75

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedPreventionBreast Cancer With Low to Intermediate HER2 Expression1
2Active Not RecruitingPreventionBreast Cancer1
2Active Not RecruitingPreventionBreast Ductal Carcinoma in Situ1
2CompletedPreventionBreast Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Targets

Drugtargets
Accelerate your drug discovery research
with our fully connected ADMET & drug target dataset.
Learn more
Accelerate your drug discovery research with our ADMET & drug target dataset
Learn more
1. HLA class I histocompatibility antigen, A-2 alpha chain
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Tap binding
Specific Function
Involved in the presentation of foreign antigens to the immune system.
Gene Name
HLA-A
Uniprot ID
P04439
Uniprot Name
HLA class I histocompatibility antigen, A-3 alpha chain
Molecular Weight
40840.41 Da

Drug created on March 19, 2008 16:18 / Updated on February 21, 2021 18:52